HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
Andrea Pascual-OliverDiego Casas DezaCamila CuaránSantiago García-LópezPilar Corsino-RocheEva Sierra-MorosPilar Olier-MartínezRicardo González-TarancónRaquel Vicente-LidónPublished in: Inflammatory bowel diseases (2023)
In our real-life cohort of IBD patients treated for the first time with anti-TNF, being an HLA-DQA1*05 carrier did not act as a predictor of response failure, either primary or secondary. The safety of anti-TNF treatment has also not been influenced by the variant.